Insight into the global market for implantable insulin pump by 2030

Dublin, 5 November 2021 (GLOBE NEWSWIRE) – The report “Implantable Insulin Pump Market by Type, Disease, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” has been added to ResearchAndMarkets.com’s offer.

The global market for implantable insulin pumps was estimated at $ 2.674 million by 2020 and is expected to reach $ 6.443 million by 2030, recording a CAGR of 9.1% from 2021 to 2030.

Implantable insulin pump is a medical device that helps deliver insulin into the abdominal cavity and stays inside the human body at all times. In addition, implanted insulin pumps help with efficient absorption of insulin. The implantable insulin pumps are expected to revolutionize the treatment of diabetic diseases and also provide a constructive solution to accurately effective artificial pancreas. There are two types of implantable insulin pumps, such as closed-loop insulin pump and open-circuit insulin pump. It is the next generation of insulin that automatically responds to altered blood sugar levels. In addition, it is a painless way to deliver insulin compared to injectable insulin, which minimizes the risk of skin irritation caused by needles.

The growth in the market for implantable insulin pumps is driven by an increase in the incidence of diabetes across the globe, an increase in the demand for implantable insulin pump and the accuracy of insulin dosing with implantable insulin pump. In addition, awareness of insulin therapy from healthcare professionals, technological advances in implantable insulin pumps, an increase in the patient’s emphasis on effective and early diabetes treatment, and increased investment in R&D for insulin pumps are expected to increase market growth during the forecast period. However, strict government regulations are expected to hamper market growth during the forecast period. Conversely, a high market growth potential in emerging markets is expected to offer lucrative opportunities during the forecast period.

The market for implantable insulin pumps is segmented by type, disease, end user and region. The market is categorized on the basis of type into closed circuit insulin pump and open circuit insulin pump. By disease, the market is divided into type 1 diabetes and type 2 diabetes. Based on the end user, the market is categorized into hospitals and home care. The hospital segment is further divided into type 1 diabetes and type 2 diabetes. The home care segment is further segmented into type 1 diabetes and type 2 diabetes. Regionally, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Important benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimates to illuminate the impending investment pockets.

  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable stakeholders to take advantage of the prevailing market opportunities.

  • A comprehensive analysis of four regions is provided to determine the existing options.

  • The key players’ profiles and growth strategies are thoroughly analyzed to understand the global market’s competitive prospects.

Key topics covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: SUMMARY

CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five-force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in the incidence of diabetes worldwide
3.5.1.2. Sedentary and unhealthy lifestyle pattern
3.5.1.3. Increase in public spending on health care
3.5.2. Restraint
3.5.2.1. Strict state rules
3.5.3. Opportunities
3.5.3.1. High market growth potential in emerging markets
3.5.4. Effect analysis
3.6. Covid-19 impact assessment on the market for implantable insulin pump

CHAPTER 4: THE MARKET FOR IMPLANTABLE INSULIN PUMPS, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Closed loop insulin pump
4.2.1. Important market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Open loop insulin pump
4.3.1. Important market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

CHAPTER 5: THE MARKET FOR IMPLANTABLE INSULIN PUMPS, BY DISEASE
5.1. Overview
5.1.1. Market size and forecast
5.2. Type 1 diabetes
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Type 2 diabetes
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: THE MARKET FOR IMPLANTABLE INSULIN PUMPS, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.2.3. Market size and forecast, by disease
6.3. Home care
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.3.3. Market size and forecast, by disease

CHAPTER 7: THE IMPLANTABLE INSULIN PUMP MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES
8.1. Apex Medical
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operational business segments
8.1.4. Product portfolio
8.2. CVS Health (Aetna Inc.)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operational business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Diabeloop SACA
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operational business segments
8.3.4. Product portfolio
8.3.5. Key strategic features and developments
8.4. DIAMESCO CO., LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operational business segments
8.4.4. Product portfolio
8.5. F. Hoffmann La Roche Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operational business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic features and developments
8.6. Insulet Corporation
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operational business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic features and developments
8.7. Johnson & Johnson
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operational business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Medtronic PLC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operational business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic features and developments
8.9. Sooil Developments Co. Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operational business segments
8.9.4. Product portfolio
8.9.5. Key strategic features and developments
8.10. Tandem Diabetes Care Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operational business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic features and developments

For more information on this report, visit https://www.researchandmarkets.com/r/usbeds

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment

Advertise